来自官方财务报表的收入、利润与现金流历史。
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | JPY 453.3B | JPY 398.8B | JPY 314.6B | JPY 555.5B | — |
| 毛利 | JPY 256.9B | JPY 245.4B | JPY 188.0B | JPY 376.6B | — |
| 营业利润（EBIT） | JPY 105.1B | JPY 29.7B | (JPY 354.8B) | (JPY 77.0B) | — |
| 净利 | JPY 106.9B | JPY 23.6B | (JPY 315.0B) | (JPY 74.5B) | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 4506 交互式查看器。 /companies/us/4506
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms